Holen Sie sich die Stockscreener-App
12.94
2.54%
0.32
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Northern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Dimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Viridian Therapeutics (VRDN) to Release Quarterly Earnings on Wednesday - Defense World
Q2 EPS Estimate for Viridian Therapeutics Lowered by Analyst - Defense World
Wedbush Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Q2 EPS Estimate for Viridian Therapeutics Reduced by Analyst - Defense World
B. Riley Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - The AM Reporter
JMP Securities Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - Defense World
Royal Bank of Canada Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $45.00 - Defense World
Q1 Earnings Estimate for VRDN Issued By HC Wainwright - Defense World
Needham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - Defense World
The Goldman Sachs Group Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - Defense World
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - BioSpace
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
What 5 Analyst Ratings Have To Say About Viridian Therapeutics - Benzinga
FDA Grants Breakthrough Therapy Status to Viridian's (VRDN) Veligrotug | VRDN Stock News - GuruFocus
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Target Price Adjusted by RBC Capita - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Ratin - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Rating | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Price Target Update by JMP Securities | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Price Target Reduced Amid Market Concerns | VRDN Stock News - GuruFocus
Needham Maintains Buy Rating on Viridian Therapeutics (VRDN) | V - GuruFocus
Needham Maintains Buy Rating on Viridian Therapeutics (VRDN) | VRDN Stock News - GuruFocus
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP - TipRanks
Thyroid Eye Disease Market Top Companies StudyHorizon - openPR.com
Bullish Viridian Therapeutics Insiders Loaded Up On US$616.3k Of Stock - simplywall.st
Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Viridian Therapeutics (VRDN) Sees Price Target Adjustment by Citizens JMP | VRDN Stock News - GuruFocus
Viridian Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating - TipRanks
Viridian Therapeutics Inc (VRDN)’s Market Momentum: Closing Strong at 13.12, Down -3.67 - DWinneX
Stifel maintains Buy on Viridian Therapeutics, $41 target By Investing.com - Investing.com India
Viridian Therapeutics Shares Fall After Q1 Net Loss Widens, Revenue Flat - marketscreener.com
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats By Investing.com - Investing.com Nigeria
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats - Investing.com
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Viridian Therapeutics, Inc.\DE SEC 10-Q Report - TradingView
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - BioSpace
Viridian Therapeutics Q1 2025 Financial Results - TradingView
Earnings Flash (VRDN) Viridian Therapeutics Posts Q1 Net Loss $0.87 a Share, vs. FactSet Est of $1 Loss - marketscreener.com
How to Take Advantage of moves in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq L - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Inc [NASDAQ: VRDN] Sees Increase in Stock Value - knoxdaily.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Viridian Therapeutics Inc (VRDN) did well last session? - uspostnews.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC - Defense World
Upward Trajectory: Viridian Therapeutics Inc (VRDN) Posts a Gaine, Closing at 13.53 - DWinneX
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70 - Defense World
HC Wainwright Reiterates Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Inc [VRDN] Shares Fall -1.82 % on Wednesday - knoxdaily.com
How did Viridian Therapeutics Inc (VRDN) fare last session? - uspostnews.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co. - Defense World
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):